Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis

What Was Tested

The paper reports a study of Leuprolide in the context of endometriosis, published as a randomized controlled trial.

Who Took Part

By PubMed's age tags, the people studied were teenagers, young adults, adults and middle-aged adults, women only.

A 24-week, open-label, randomized, multicenter study of DNG versus LA in women with endometriosis-related pain was assessed for outcomes such as responder rates (using predefined thresholds of pain relief), changes in single symptoms/signs and sum scores from the Biberoglu and Behrman (B&B) scale, clinical laboratory parameters, and measures of quality of life.

How the Study Was Run

The researchers set it up as a randomized, open-label and multicenter study.

Random assignment meant chance, not the researchers, decided who got Leuprolide and who got the comparison, which limits bias.

Everyone knew when Leuprolide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Running at several centres spread the Leuprolide study over different clinics and patient groups.

What Was Measured

The subject headings attached to it are Antineoplastic Agents, Hormonal, Dysmenorrhea, Endometriosis, Estrogens, Leuprolide, Nandrolone and Pelvic Pain.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Leuprolide in people with endometriosis.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2012 (International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics), a journal based in United States.

More context: the Leuprolide compound page, Endometriosis research.